Category: South Africa

Posted on

Aztiq Promotes David Olafsson, Danny Major and Eunsun Choi to Partner

REYKJAVIK, Iceland, July 06, 2026 (GLOBE NEWSWIRE) — Aztiq today announced the promotion of David Olafsson, Danny Major and Eunsun Choi to Partner, recognizing their significant contributions to Aztiq’s growth, investment activities and long-term value creation across the healthcare ecosystem.

Aztiq is an investment company focused on working with purpose-driven pharmaceutical and biotechnology companies dedicated to improving the lives of people around the world. The promotions reflect Aztiq’s continued commitment to building a strong, experienced and collaborative leadership team with deep sector expertise across healthcare, investment, corporate development, finance, M&A and legal execution.

“David, Danny and Eunsun have each played an important role in Aztiq’s development and in supporting our portfolio companies” said Robert Wessman, Founder and Chairman of Aztiq. “Their promotions to Partner recognize not only their individual achievements, but also the trust, judgment and dedication they bring to Aztiq and our partners and portfolio companies. They embody the entrepreneurial, hands-on and long-term approach that defines Aztiq.”

As Partners, David Olafsson, Danny Major and Eunsun Choi will continue to support Aztiq’s investment activities, portfolio company development and strategic initiatives to advance the firm’s healthcare-focused investment platform.

Aztiq press contacts

[email protected]

About Aztiq

Aztiq is an investment company focused on working with purpose-driven pharmaceutical and biotechnology companies dedicated to improving the lives of people around the world. With deep healthcare experience, an entrepreneurial mindset and a flexible investment approach, Aztiq partners with companies to unlock sustainable, long-term value and create positive change for patients and the global healthcare ecosystem.


GlobeNewswire Distribution ID 1001211449

Posted on

CGTN: Why the world is asking: What makes the CPC work?

BEIJING, July 04, 2026 (GLOBE NEWSWIRE) — On the 105th anniversary of the founding of the Communist Party of China, CGTN has published an article examining why the CPC continues to attract growing international attention. The article explores how China’s development path, governance model and global vision are reshaping global perceptions of the CPC and offering fresh perspectives on modernization and global governance.

When the international community looks at the Communist Party of China (CPC), what do they see? The latest CGTN global polls on evaluations of the CPC’s role offer a compelling answer. Respondents ranked “strong leadership” as their strongest impression of the Party, followed by “a positive force for maintaining global stability” and “a representative of developing countries’ interests.”

The findings suggest that global attention to the CPC has extended far beyond China’s economic miracles to its governance model and its philosophy in addressing shared global challenges. These themes also took center stage during a speech by Xi Jinping, general secretary of the CPC Central Committee, marking the Party’s 105th anniversary on July 1. The speech by Xi, also Chinese president and chairman of the Central Military Commission, resonated deeply with international observers.

“Chinese modernization has shattered the myth that modernization equals Westernization.” That is how Geeganage Weerasinghe, general secretary of the Communist Party of Sri Lanka, interpreted Xi’s latest speech.

His observation echoes a central message delivered by Xi: that the CPC has led the Chinese people in creating “a new form of human civilization” and expanding the path to modernization for developing countries. For decades, modernization was widely viewed through a Western lens. China’s experience, however, offers a different perspective.

Zheng Changzhong, a professor at Fudan University, noted that China’s development demonstrates that modernization is not a one-size-fits-all process. Guided by people-centered governance, long-term planning and policy continuity, the CPC has steered the world’s second-largest economy while maintaining long-term social stability.

The CPC’s governance philosophy has drawn attention from overseas observers. Following a recent visit to China, Massimiliano Ay, general secretary of the Communist Party of Switzerland, was most impressed by a Party “deeply rooted among the people.” Richard Abitbol, a French administrative expert, highlighted that China’s predictable policy continuity gives businesses the confidence to make long-term investments in innovation.

The growing recognition is also reflected in survey data. According to a CGTN poll, 63.9 percent of respondents attributed China’s modernization achievements to the CPC’s scientific decision-making, while 63.7 percent of respondents from the Global South believed the Party provides a viable alternative to the Western development path.

A global vision beyond zero-sum mindsets

Following Xi’s speech, Robert Lawrence Kuhn, chairman of the Kuhn Foundation, said his two keywords from the address were “stability” and “confidence.” At a time when the world is fraught with volatility and shocks, he noted that China’s external policy direction has remained notably consistent.

This consistency is grounded in the CPC’s global vision, which has, as always, made it its mission to pursue progress for humanity and great harmony for the world. Guided by this vision, the CPC has rejected zero-sum thinking and consistently provided Chinese solutions for global peace, development and governance.

In his address, Xi reiterated China’s commitment to injecting positive energy into world peace and development. He called on the Party to uphold the common values of humanity, advance the Global Development Initiative (GDI), the Global Security Initiative, the Global Civilization Initiative and the Global Governance Initiative, and continuously promote the building of a community with a shared future for humanity.

Quoting Xi’s statement that China is “a builder of world peace, a contributor to global development, and a defender of the international order,” Kawa Mahmoud, president of the Iraq-headquartered Global Civilization Initiative Research Center, said China’s commitment to multilateralism is particularly valuable at a time when unilateralism is on the rise. Wirun Phichaiwongphakdee, director of the Thailand-China Research Center of the Belt and Road Initiative, stressed Xi’s vision of building a community with a shared future for humanity and that the four global initiatives reflect the CPC’s global responsibility and contribute Chinese wisdom to human progress.

Beyond rhetoric, the CPC’s global vision is backed by action. The Party has established regular ties with over 700 political organizations in more than 170 countries. Furthermore, China has introduced zero-tariff treatment for all least developed countries and African countries with which it has diplomatic relations, launched over 1,800 cooperation projects under the GDI framework and remains the second-largest contributor to UN peacekeeping operations.

For many outside China, the question is no longer simply how the CPC transformed China but increasingly what its experience may offer to a world searching for new paths to development and cooperation.

https://news.cgtn.com/news/2026-07-03/Why-the-world-is-asking-What-makes-the-CPC-work–1OtVWfpQu64/p.html

CGTN Digital
[email protected]

GlobeNewswire Distribution ID 9756957

Posted on

Starlight Children’s Foundation wins British F1® Allwyn Global Community Award to make hospital stays kinder for children

F1® Allwyn Global Community Award 2026
The F1® Allwyn Global Community Award 2026 trophy presented to Jonny Wright and Laura Walsh from winning local charity Starlight Children’s Foundation at the FORMULA 1® PIRELLI BRITISH GRAND PRIX 2026 at Silverstone, UK.

The F1® Allwyn Global Community Award 2026 trophy presented to Jonny Wright and Laura Walsh from winning local charity Starlight Children’s Foundation
SILVERSTONE, United Kingdom, July 02, 2026 (GLOBE NEWSWIRE) — Starlight Children’s Foundation has been named the British winner of the F1® Allwyn Global Community Award at the FORMULA 1® PIRELLI BRITISH GRAND PRIX 2026. The charity, which helps critically ill children in hospital play, laugh and do the things they love while receiving treatment, has been awarded €100,000 from Allwyn AG, the multi-national lottery-led entertainment company whose UK subsidiary operates The National Lottery. The Award will help Starlight to further its innovative approach to children’s care.

Many children in the UK are struggling with the emotional weight of medical care, with around 1.4 million vulnerable to healthcare-related trauma*. For a child, fear can feel overwhelming, often leading to deep distress that can make their treatment journey much harder and leave lasting marks on their wellbeing. However, Starlight creates moments of escape from these difficult situations.

The €100,000 donation from Allwyn will further Starlight’s pioneering pilot project – the introduction of the new ‘Health Play Practice Educator’ role to embed consistent play-informed care across the NHS, through activities and experiences. It will also facilitate the training of up to 1,000 professionals in specialised care. Starlight was commended by the judging panel for its spirit of innovation – a value shared by both Allwyn and Formula 1 – as well as the project’s scalability and potential for other organisations to replicate.

Alastair Ruxton, Chief Impact Officer at Allwyn UK and F1® Allwyn Global Community Award judge, said: “We are proud to award the F1® Allwyn Global Community Award to the Starlight Children’s Foundation. As judges, we were impressed by their spirit of innovation and their pioneering approach to tackling healthcare-related trauma many children face. Allwyn is proud to champion this kind of bold, systemic change, and it demonstrates how the impact of our global programme extends far beyond the racetrack.”

Cathy Gilman, CEO, Starlight said: “We are thrilled and deeply honoured to receive the F1® Allwyn Global Community Award. Hospitals and medical procedures can be incredibly scary and traumatising for children, but our new role will help hospitalised children understand, cope, and heal. This incredible €100,000 donation from Allwyn will directly fund our ambition to make hospital stays kinder and treatments gentler for seriously ill children.”

Ellen Jones, Head of ESG at Formula 1 and F1® Allwyn Global Community Award judge, added: “At Formula 1®, we are committed to leveraging our platform to drive transformative change within our local communities. The Starlight Children’s Foundation aligns closely with our broader social impact priorities, especially our commitment to using bold, innovative approaches to solve complex challenges in areas such as healthcare. Its new ‘Health Play Practice Educator’ role offers a scalable model for long-term impact.”

Starlight Children’s Foundation is the third non-profit to be recognised by the F1® Allwyn Global Community Award in 2026. Following a highly successful inaugural year in 2025, this year’s programme launched in May with Canadian charity La Tablée des Chefs winning the first Award at the FORMULA 1® LENOVO GRAND PRIX DU CANADA for its vital work in fighting food insecurity, by recovering and redistributing meals to vulnerable families. Last week, Allwyn awarded Austrian non-profit Sindbad Mentoring at the FORMULA 1® LENOVO AUSTRIAN GRAND PRIX 2026 to supercharge its mission to level the playing field for young people, boost social mobility and inspire them to pursue their dream career pathways, especially in STEM.

More NGOs will be recognised across the Grand Prix race locations this season in the Netherlands, Austin, Mexico City and Las Vegas. Later in the year, Formula 1® fans will have the chance to cast their vote on their favourite winning initiatives as part of Allwyn’s plan to bring these fans closer to the programme.

Notes to editors

*Starlight Cause of Trauma report 2025

About Allwyn
Allwyn AG is a multi-national gaming entertainment company, lottery-led and with leading market positions and trusted brands across Europe and North America, listed on Euronext Athens. Its purpose is to make play better for all by focusing on innovation, technology, player safety and returning more to good causes across a growing casual gaming entertainment portfolio.

Allwyn Entertainment Ltd (Allwyn UK), a separate subsidiary of Allwyn AG, is the operator of The National Lottery in the UK.

Media enquiries [email protected]

About Allwyn’s partnership with Formula 1®
The multi-year partnership with Formula 1® represents a drive towards increased global awareness for Allwyn, with the sport’s 24 races across the globe, 750 million fans, and 96 million social media followers, as well as its reach across broadcast channels and entertainment outlets.

The partnership will reinforce Allwyn’s position as an international brand driving community impact across the world, in support of its global growth plans.

At the heart of the partnership is the development of initiatives that will support the company’s ambition to be a positive contributor to society globally. With Allwyn and Formula 1® equally committed to empowering fans and local communities, the partnership will give Allwyn the opportunity to utilise the sport’s ever-growing international fan base to celebrate those making positive change, sharing these inspiring stories on a global level.

About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: FWONA, FWONK, LLYVA, LLYVK) attributed to the Formula One Group tracking stock. The F1 logo, F1 Formula 1® logo, Formula 1®, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1® company. All rights reserved.

Press contacts

Formula 1® Press Office

E: [email protected]

T: @f1media

Further information about the F1® Allwyn Global Community Award, including eligibility criteria and the selection process, can be found on our website: https://www.allwyn.com/responsibility/community-award.

About Starlight
Starlight is the UK’s leading charity working to put play at the heart of every child’s healthcare. Play takes the scare out of children’s healthcare, making them more resilient and receptive to treatment. We provide play resources, campaign for better health play services, and build best practice with frontline paediatric professionals.

The problem is fear. The answer is play. It’s time to put play into practice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01194d47-e114-47fa-b45a-eb0c0bcfbfc9

GlobeNewswire Distribution ID 1001210923

Posted on

Changan Automobile Announces Global Strategic Partnership with the Portugal National Football Team, Leveraging Global Sports IP to Deepen MEA Market Layout

DUBAI, United Arab Emirates, July 02, 2026 (GLOBE NEWSWIRE) — As the grand 2026 North American football spectacle unfolds and captures global attention on the pitch, powerhouse Portugal takes to the field once again. Ahead of the tournament’s kickoff, Changan Automobile entered into a landmark global strategic partnership with the Portuguese Football Federation (FPF), becoming the Official Global Partner of the Portugal National Football Team.

Changan Automobile Announces Global Strategic Partnership with the Portugal National Football Team
Representatives of Changan Automobile and the Portuguese Football Federation at the global strategic partnership announcement event

Changan Automobile entered into a landmark global strategic partnership with the Portuguese Football Federation (FPF), becoming the Official Global Partner of the Portugal National Football Team.

Rooted in the shared brand ethos of Stay in the Game, Portuguese football boasts profound youth training heritage, consistently nurturing top-tier football talents and demonstrating unyielding perseverance and enterprising spirit on the pitch. This sporting spirit highly aligns with Changan Automobile’s long-term development philosophy. Over its 45-year development journey, Changan has adhered to long-term value orientation, focusing on intelligent mobility and new energy R&D. Empowered by solid technological accumulation and brand heritage, Changan has steadily advanced its global layout and built a solid and sustainable development framework for overseas markets.

Boasting an extensive global fanbase, the Portugal National Team commands far-reaching influence worldwide, notably across the MEA region. Building on football’s deep cultural resonance across the region, Changan works closely with local dealer network to roll out a comprehensive series of football-themed marketing initiatives, including fan viewing parties, community engagement programs, and immersive brand experiences. In parallel, football-inspired test drive events will integrate vehicle experiences with the excitement of the sport, creating engaging lifestyle-oriented interactions with consumers.

As a core strategic growth hub for Changan’s global expansion, the MEA region occupies a pivotal position in the brand’s overseas deployment. By combining a world-class international football IP with localized retail experiences, Changan Automobile is using football as a universal cultural bridge to transcend geographical and cultural boundaries. Through the shared language of sport, the brand is fostering authentic emotional connections with local consumers, embedding itself naturally into everyday life while reinforcing its long-term commitment to the Middle East and Africa through high-quality products, dependable service, and a consistently trusted ownership experience.

Changan Automobile Becomes The Official Global Partner of the Portugal National Football Team
Promotional visual featuring Portugal National Team players and Changan Automobile vehicles as part of the global partnership campaign.

Changan Automobile entered into a landmark global strategic partnership with the Portuguese Football Federation (FPF), becoming the Official Global Partner of the Portugal National Football Team.

Tailored to the diverse travel habits and consumer needs of MEA users, Changan’s rich product matrix covers multiple segmented markets. The CHANGAN G318 delivers robust all-terrain performance, ideal for local outdoor exploration and long-distance travel. The DEEPAL S05 balances stylish design and high energy efficiency, perfectly matching urban commuting and family travel demands. Meanwhile, the sporty, intelligent UNI-S caters to young local consumers’ pursuit of trendy, smart urban mobility. What’s more, Changan boasts an extensive range of additional compelling models to cater to the full spectrum of regional consumer demands and diverse personal preferences.

Moving forward, Changan will continue to leverage sports marketing as a lasting cultural bridge to strengthen emotional resonance with MEA consumers. By integrating cutting-edge intelligent mobility technologies and user-centric brand experiences, the brand will work hand in hand with regional users to create a smarter, more sustainable and experience-driven future of mobility.

Company Contact Information:
Chongqing Changan Automobile Co., Ltd.
E-mail: [email protected]

Photos are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2523e5de-e69d-4d1f-a268-bbb1b6f41be5
https://www.globenewswire.com/NewsRoom/AttachmentNg/e357912a-e1b9-446d-af0c-32e6d74f4ec6

GlobeNewswire Distribution ID 9756223

Posted on

Jeppesen ForeFlight Unveils Agentic AI Strategy and Engine for the Aviation Industry

Jeppesen ForeFlight Airflow™

Jeppesen ForeFlight Airflow™

New Solutions for Every Aviation Segment Launching in 2026
Jeppesen ForeFlight Airflow™ Introduced as Company’s Aviation Intelligence Engine

AUSTIN, Texas, July 01, 2026 (GLOBE NEWSWIRE) — Jeppesen ForeFlight today unveiled its aviation-centric AI engine, the foundation of its strategy to bring responsible artificial intelligence to all sectors of aviation. Jeppesen ForeFlight Airflow™ has been developed over the last several years, backed by decades of deep domain experience, industry-leading data, and capabilities spanning crew and fleet planning, day-of-flight operations, and flight deck solutions.

Jeppesen ForeFlight Airflow™ is the foundational agentic AI engine combining commercially available data, segregated proprietary customer data, and extensive domain knowledge including safety, certification expertise, and contextual reasoning across every aviation market. Built on an open architecture and designed to be model agnostic, Jeppesen ForeFlight Airflow™ gives customers full flexibility in how they adopt AI, whether by integrating their own agents, leveraging third-party solutions, or deploying Jeppesen ForeFlight’s native agents. Customers can move at their own pace, at lower cost, and with as much or as little human control over key decisions as their operations require. This flexibility, paired with the company’s reach across crew, fleet, operations, and flight deck performance, distinguishes Jeppesen ForeFlight from generic AI platforms and single-point solutions.

The company is already previewing its first product in the General Aviation market, the ForeFlight AI Connector, an MCP server connecting ForeFlight Mobile to a customer’s existing OpenAI ChatGPT environment. Users can query their personal AI for flight plans and refueling options, or build AI-connected tools and workflows using their data in ForeFlight Mobile. The company intends to expand this feature to other popular AI applications such as Google’s Gemini and Anthropic’s Claude so users can use the experience layer of their choosing.

Later this year, Jeppesen ForeFlight Airflow™ will debut its first offerings to the Commercial and Business aviation segments, with military-focused capabilities to follow.

“General AI is confident, but often wrong. In our industry, these mistakes cascade into costly, dangerous, or catastrophic outcomes. Artificial intelligence is not enough for this industry, we need aviation intelligence: the assurance that the right data, right context, and right reasoning are applied every time, and always cross-checked and filtered through industry safety and governance protocols,” said Brad Surak, CEO, Jeppesen ForeFlight. “We have helped the industry evolve from paper to digital to mobile, and we are bringing to market a highly differentiated AI offering in Jeppesen ForeFlight Airflow™ that customers can deploy on their own terms and timelines, at significantly lower IT costs than previous industry transitions.”

Unlike other aviation industry approaches, Jeppesen ForeFlight Airflow™ differentiates and delivers in five critically important areas:

  • Reasons in Context – Trusted workflows that fully grasp how the aviation industry actually operates, not just what tended to happen last time.
  • Reasons from Certified Inputs – Provenanced intelligence: every outcome carries the regulatory authority and certified accuracy of Jeppesen ForeFlight’s longstanding aviation data and capabilities that much of the industry already relies on for safe and optimized operations.
  • Carries a Visible Why-Trail – Every recommendation reveals the underlying causal logic, from specific inputs and operational constraints through evaluated alternatives and associated uncertainty. This auditable decision trace creates a continuous improvement cycle, improving outcomes over time.
  • Operates Inside the company’s Safety Management System (SMS) – built on the safety framework aviation already runs on via our patent-pending Aviation Intelligence SMS (AI-SMS).
  • Human-centered Judgments – AI handles the volume. Customers select how much automation they need, with an assurance that humans remain in control of decision-making wherever necessary.

“We are leveraging decades of experience delivering data and software solutions globally, which compounds virtually every second on the 60 million flights we serve annually. But most importantly, our AI earns trust one decision at a time,” Surak added.

Jeppesen ForeFlight Airflow™ aviation context graph is the most authoritative record of how aviation operates. When our AI reasons from this foundation, every output inherits that regulatory provenance that is purpose-built within Jeppesen ForeFlight’s AI SMS: encompassing hazard identification, safety trend analysis, predictive risk modeling, and the integration of operational data with safety records in ways traditional tools cannot support.

Operators interested in early co-development access should contact their Jeppesen ForeFlight account executive or visit ai.jeppesenforeflight.com.

About Jeppesen ForeFlight

Jeppesen ForeFlight provides the data, software, and insights that power every segment of aviation. Pilots, operators, and flight crews trust us to plan, navigate, monitor, and optimize more than 60 million commercial, military, business, and general aviation flights each year. Our platforms support crew, fleet, and flight planning; network and operations management; and flight deck solutions. Our navigation data remains the global standard. From inventing paper charts a century ago to leading today’s AI-enabled era, we deliver deep domain expertise with unmatched insights as the platform for the aviation industry.

For Media Inquiries Please Contact

Brett Griffin
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c1d18f4a-bf05-4987-bd0a-dc8f2f3edf4b

GlobeNewswire Distribution ID 9755716

Posted on

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

  • Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers 
  • Across both studies, mogamulizumab was associated with improved survival outcomes compared to standard of care

PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) — Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). These findings, which drew on clinical trial and real-world data, expand the growing body of evidence supporting mogamulizumab use and address critical information gaps where comparative survival data have been limited. The research was funded by Kyowa Kirin Co. Ltd (TSE: 4151).

“Indirect treatment comparisons help to bridge critical evidence gaps in MF and SS, giving clinicians a clearer picture of long-term outcomes in real-world practice,” said Professor H. Miles Prince, Principal Investigator, Peter MacCallum Cancer Centre in Melbourne, Australia. “This deeper understanding enables us to make informed treatment decisions and ultimately provide more personalized, effective care for our patients.”

MF and SS are rare, progressive forms of CTCL associated with substantial morbidity in advanced stages and often require multiple lines of treatment. In the phase 3 MAVORIC trial, mogamulizumab improved progression-free survival versus vorinostat in adult patients with relapsed or refractory MF or SS, but a high rate of treatment crossover limited direct assessment of overall survival.

To address this limitation, two independent studies used MAVORIC and real-world data to estimate comparative OS using ITC methods while accounting for patient differences across treatment groups and data sources. These findings aim to help address evidence gaps that limit access in some countries and support informed treatment decision-making.

“In rare diseases like CTCL, clinical trials are often not designed to evaluate long-term treatment outcomes like overall survival,” said Dr. Angela Williams, PhD, Global Head Health Economics and Outcomes Research at Kyowa Kirin. “By applying advanced analytical approaches, we can integrate clinical trial and real-world data to better assess the long-term impact of a treatment like mogamulizumab on overall survival and other outcomes. This approach reflects our continued commitment to advancing research that informs treatment decisions in rare, hard-to-treat hematologic malignancies like CTCL, helping to improve the lives of patients and their care partners.”

ITC Methodology and Results

In two separate ITC studies, researchers analyzed survival outcomes in cohorts of patients with relapsed or refractory MF or SS by comparing patient-level data from the mogamulizumab arm of the MAVORIC trial (n=186) with real-world registry data from Australia and Denmark. Vorinostat, the active comparator in MAVORIC, is part of the standard of care in Australia but unavailable in Denmark. Key limitations of these analyses include the retrospective nature of the studies and potential differences in advances and standards of care over time.

Australia (Campbell BA, et al): Real-world data from the Australian Peter MacCallum Cancer Centre Cutaneous Lymphoma database included 67 patients treated with vorinostat between January 2005 and November 2024. After adjusting for baseline differences:

  • Median OS was not reached for patients receiving mogamulizumab, compared with 31.0 months for patients receiving vorinostat.
  • Mogamulizumab was associated with a significantly lower risk of death compared with vorinostat (hazard ratio [95% confidence interval]: 0.48 [0.30, 0.76]; p=0.002).
  • Median time to next treatment (TTNT) was numerically longer with mogamulizumab versus vorinostat (9.13 months vs. 5.82 months; hazard ratio [95% confidence interval]: 0.76 [0.52, 1.11]; p=0.20), though this difference was not statistically significant.

Denmark (Morgante N, et al): Real-world data from Danish national registries included 209 patients receiving standard of care treatment between January 1996 and April 2024. After statistical weighting:

  • Patients receiving mogamulizumab did not reach median OS, compared with 17.0 months for patients receiving standard of care.
  • Mogamulizumab was associated with a significantly lower risk of death versus standard of care (hazard ratio [95% confidence interval]: 0.38 [0.25, 0.59]; p<0.001).

U.S. POTELIGEO (mogamulizumab-kpkc) Indication

POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

Infections: Monitor patients for signs and symptoms of infection and treat promptly.

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information.

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.  You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

COR-US-POT-0016 June 2026

CONTACT:

Susan Thiele
Head of Therapeutic Communications, North America
[email protected]

GlobeNewswire Distribution ID 9753760